Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 14Pancreatic Neoplasms 5Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Non-Small Cell Lung Cancer 2Uterine Cervical Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pan-tumor 1Neoplasm Metastasis 1Locally Advanced Gastric or Gastroesophageal Junction Cancer 1Klatskin Tumor 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1

Interventions

andecaliximab 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Injections 1Immunotherapy, Adoptive 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastric Adenocarcinoma × S 1 (combination) × Clear all
NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡